BiotechTube

Letermovir 240 mg Oral Tablet

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infections, Cytomegalovirus

Conditions

Infections, Cytomegalovirus

Trial Timeline

Oct 1, 2023 → Apr 1, 2027

NCT ID
NCT06057194

About Letermovir 240 mg Oral Tablet

Letermovir 240 mg Oral Tablet is a phase 2 stage product being developed by Merck for Infections, Cytomegalovirus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06057194. Target conditions include Infections, Cytomegalovirus.

What happened to similar drugs?

20 of 20 similar drugs in Infections, Cytomegalovirus were approved

Approved (20) Terminated (3) Active (0)
✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved
✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
✅Ceftaroline fosamil + Ceftriaxone plus vancomycinAstraZenecaApproved
✅Kaletra + Isentress + Pre-study antiretroviral regimenMerckApproved
✅HPV9vMerckApproved
✅Vancomycin + Daptomycin + Semi-Synthetic PenicillinMerckApproved
✅Daptomycin + VancomycinMerckApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06057194Phase 2Recruiting

Competing Products

20 competing products in Infections, Cytomegalovirus

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
AAVLP-HPV + Placebo2A PharmaPhase 1
19
VN-0200 + PlaceboDaiichi SankyoPhase 1
29
VN-0200Daiichi SankyoPhase 2
35
MicafunginAstellas PharmaPre-clinical
26
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
43
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
43
MicafunginAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 1
29
Micafungin + PlaceboAstellas PharmaPhase 3
32
Cefiderocol + Standard of CareShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
29
Cefiderocol + Standard of CareShionogiPhase 2
35
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
40
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
GW810781ShionogiPhase 2
35
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29